Tu compromiso con el tratamiento eficaz del acné marca la diferencia en la calidad de vida de tus pacientes. Esperamos que este estudio clínico te aporte información valiosa para tu práctica diaria.
AKLIEF® | Galderma 2025 - Todos los Derechos Reservados
Indication: AKLIEF® (trifarotene) Cream, 0.005% is indicated for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.⁴ BL, baseline. *Based on acne scar count with a topical therapy. A randomized, split-face, double-blind study of patients (age: 17–34 years, N=121) with moderate-to-severe facial acne, with acne scars present, treated with AKLIEF® Cream or vehicle once daily for 24 weeks. The primary endpoint was absolute change from baseline (BL) in total atrophic acne scar count per half face at Week 24. Other endpoints were atrophic acne scar counts, acne lesion counts, Scar Global Assessment, Investigator’s Global Assessment and success rates. Patient-reported outcomes included self-assessment of clinical acne-related scars questionnaire at BL, Week 12, and Week 24. The total atrophic acne scar count was 11.4 at BL vs. 5.4 ± 5.6 at Week 24 with AKLIEF® Cream (mean percentage change: 55.2%). The total acne lesion count was 37.3 at BL vs. 11.0 at Week 24 with AKLIEF® Cream (mean percentage change: 70.0%). This study was sponsored by Galderma.¹⁻⁵ References: 1. Schleicher S, et al. Dermatol Ther (Heidelb). 2023;13(12):3085–3096. 2. Dreno B, et al. J Dermatol. 2018;19(2):275–286. 3. Loss MJ, et al. Dermtol Ther (Heidelb). 2018;8:245–257. 4. AKLIEF® 50 microgram/g cream [Summary of product characteristics]. September 2024. 5. Galderma Data on File. START study Clinical Study Report: RD.06.SPR.202395 (May 2023) (Listing 16.2.6.6).
